FrancophonIA/ELRC3.0 huggingface dataset:
English: Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days.
Slovenian: Pri mačkah se občasno pojavijo začasna apatija (izguba interesa za okolico) in anoreksija (izguba teka) ter hipertermija (povišana telesna temperatura), ki traja en dan ali dva.
English: There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.
Slovenian: Na mestu injiciranja se lahko pojavi lokalna reakcija z rahlimi bolečinami ob dotiku, srbečico ali edemom (oteklino), ki izgine v enem do dveh tednih.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RC exceed the risks for the approved indications and recommended that Purevax RC be given a marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Purevax RC večje od z njim povezanih tveganj za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
English: When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign' and makes antibodies against them.
Slovenian: Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse kot „tujke“ in proti njim tvori protitelesa.
English: In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above.
Slovenian: V laboratorijskih pogojih je bilo dokazano, da zdravilo Purevax RC ščiti pred zgoraj navedenimi boleznimi.
English: • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
Slovenian: • inaktivirane (uničene) antigene proti kalicivirozi (seva FCV 431 in G1).
English: In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination.
Slovenian: V terenskih študijah zdravila Purevax RC so proučevali osnovno shemo cepljenja (dve injekciji v razmiku od treh do štirih tednov) in obnovitveno cepljenje.
English: The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus and calicivirus.
Slovenian: Učinkovitost zdravila Purevax RC so proučili v več preskušanjih v laboratorijskih pogojih, v katerih so mačke cepili in okužili s herpesvirusom in kalicivirusom.
English: Other information about Purevax RC:
Slovenian: Druge informacije o zdravilu Purevax RC:
English: Purevax RC is a vaccine.
Slovenian: Zdravilo Purevax RC je cepivo.
English: Purevax RC contains small amounts of weakened or killed viruses that cause feline rhinotracheitis and calicivirosis.
Slovenian: Zdravilo Purevax RC vsebuje majhne količine oslabljenih ali uničenih virusov, ki povzročajo rinotraheitis in kalicivirozo mačk.
English: Purevax RC should not be used in pregnant cats.
Slovenian: Zdravilo Purevax RC se ne sme uporabljati pri brejih mačkah.
English: Purevax RC is used to vaccinate cats from the age of 8 weeks against:
Slovenian: Zdravilo Purevax RC se uporablja za cepljenje mačk, starih osem tednov ali več, proti:
English: • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).
Slovenian: • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus).
English: In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly.
Slovenian: V študiji obnovitvenega cepljenja so ravni protiteles proti herpesvirusu rinotraheitisa in kalicivirusu ostale stabilne na visoki vrednosti ali pa so se rahlo zvišale.
English: Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Slovenian: Zdravilo Purevax RC je na voljo v obliki liofilizata (pelet, posušenih v zamrznjenem stanju) in vehikla za pripravo suspenzije za injiciranje.
English: For a full list of the side-effects reported with Purevax RC, see the package leaflet.
Slovenian: Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Purevax RC, glejte navodilo za uporabo.
English: In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection.
Slovenian: V terenski študiji osnovnega cepljenja so se zvišale ravni protiteles proti okužbi s herpesvirusom rinotraheitisa in kalicivirusom mačk.
English: Purevax RC is a veterinary vaccine that contains:
Slovenian: Zdravilo Purevax RC je cepivo, ki se uporablja v veterinarski medicini in vsebuje:
English: What is the risk associated with Purevax RC?
Slovenian: Kakšna tveganja so povezana z zdravilom Purevax RC?
English: What benefit has Purevax RC shown during the studies?
Slovenian: Kakšne koristi zdravila Purevax RC so se pokazale v študijah?
English: Why has Purevax RC been approved?
Slovenian: Zakaj je bilo zdravilo Purevax RC odobreno?
English: Feline viral rhinotracheitis (live attenuated) and feline calicivirosis (inactivated) vaccine
Slovenian: Cepivo proti virusnemu rinotraheitisu mačk (živo oslabljeno) in kalicivirozi mačk (oslabljeno)
English: What is Purevax RC used for?
Slovenian: Za kaj se zdravilo Purevax RC uporablja?
English: How has Purevax RC been studied?
Slovenian: Kako je bilo zdravilo Purevax RC raziskano?
English: What is Purevax RC?
Slovenian: Kaj je zdravilo Purevax RC?
English: How does Purevax RC work?
Slovenian: Kako zdravilo Purevax RC deluje?
English: Invented name Strength Pharmaceutical Form Route of Administration
Slovenian: Jakost Farmacevtska oblika
English: Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09- like strain (A/Brisbane/10/2010, wild type)
Slovenian: Površinski antigeni virusa gripe (hemaglutinin in nevraminidaza)*, inaktivirani, naslednjih sevov: Sevu A/California/7/2009 (H1N1)pdm09 podoben sev (A/Brisbane/10/2010, divji tip)
English: * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin
Slovenian: * razmnoženi v celicah pasjih ledvic Madin Darby (MDCK) ** hemaglutinin
English: A/Switzerland/9715293/2013 (H3N2) - like strain (A/South Australia/55/2014, wild type)
Slovenian: Sevu A/Switzerland/9715293/2013 (H3N2) podoben sev (A/South Australia/55/2014, divji tip)
English: B/Phuket/3073/2013 - like strain (B/Utah/9/2014, wild type)
Slovenian: Sevu B/Phuket/3073/2013 podoben sev (B/Utah/9/2014, divji tip)
English: 2 x 10 pre-filled syringes (Luer Cone) + 20 needles
Slovenian: 2 x 10 napolnjenih injekcijskih brizg (Luer Cone) + 20 igel
English: 1 pre-filled syringe (Luer Lock) + 1 needle
Slovenian: 1 napolnjena injekcijska brizga (Luer Lock) + 1 igla
English: 1 pre-filled syringe (Luer Cone)
Slovenian: 1 napolnjena injekcijska brizga (Luer Cone)
English: 2 x 10 pre-filled syringes (Luer Lock)
Slovenian: 2 x 10 napolnjenih injekcijskih brizg (Luer Lock)
English: 1 pre-filled syringe (Luer Cone) + 1 needle
Slovenian: 1 napolnjena injekcijska brizga (Luer Cone) + 1 igla
English: 1 pre-filled syringe (Luer Lock)
Slovenian: 1 napolnjena injekcijska brizga (Luer Lock)
English: 2 x 10 pre-filled syringes (Luer Cone)
Slovenian: 2 x 10 napolnjenih injekcijskih brizg (Luer Cone)
English: 10 pre-filled syringes (Luer Cone) + 10 needles
Slovenian: 10 napolnjenih injekcijskih brizg (Luer Cone) + 10 igel
English: 10 pre-filled syringes (Luer Cone)
Slovenian: 10 napolnjenih injekcijskih brizg (Luer Cone)
English: 10 pre-filled syringes (Luer Lock)
Slovenian: 10 napolnjenih injekcijskih brizg (Luer Lock)
English: 10 pre-filled syringe (Luer Lock) + 10 needles l t o r
Slovenian: 10 napolnjenih injekcijskih brizg (Luer Lock) + 10 igel o č
English: Invented name Strength Pharmaceutical Form
Slovenian: Zaščiteno ime Jakost Farmacevtska oblika
English: EU numbers
Slovenian: Številka EU
English: Route of administration
Slovenian: Pot uporabe Ovojnina
English: Following the European Commission Decision the Risk Management Plan should be submitted with any new application for extending the indication regarding the treatment of mania in bipolar disorder, as relevant.
Slovenian: V skladu z odločbo Evropske komisije je treba načrt za obvladovanje tveganja predložiti z vsako novo vlogo za razširitev indikacije v zvezi z zdravljenjem manije pri bipolarni motnji, kot je primerno.
English: CONDITIONS OF THE MARKETING AUTHORISATIONS National Competent Authorities, coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Slovenian: POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM Pristojni nacionalni organi, katerih delo usklajuje referenčna država članica, kadar je primerno, zagotovijo, da imetniki dovoljenj za promet z zdravilom izpolnjujejo naslednje pogoje:
English: ANNEX IV CONDITION OF THE MARKETING AUTHORISATIONS
Slovenian: DODATEK IV POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: This can result in serious vision loss and even blindness.
Slovenian: To lahko povzroči resno poslabšanje vida in celo slepoto.
English: Further information on Rhokiinsa can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rhokiinsa
Slovenian: Nadaljnje informacije o zdravilu Rhokiinsa so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/rhokiinsa.
English: The European Medicines Agency therefore decided that Rhokiinsa's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Rhokiinsa večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: What measures are being taken to ensure the safe and effective use of Rhokiinsa?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rhokiinsa?
English: The safety of Rhokiinsa will be further investigated in a study.
Slovenian: Varnost zdravila Rhokiinsa bodo dodatno raziskali v študiji.
English: However, side effects on the eye were more frequent than those of timolol, and this may lead people to stop treatment.
Slovenian: Kljub temu so bili neželeni učinki na oko pogostejši kot učinki pri timololu, zaradi česar lahko ljudje prenehajo zdravljenje.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rhokiinsa have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rhokiinsa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: It is available as an eye-drop solution (200 microgram/ml) and the dose is one drop in the affected eye once a day, in the evening.
Slovenian: Na voljo je v obliki raztopine za kapljice za oči (200 mikrogramov/ml), ki se daje v odmerku ene kapljice v obolelo oko enkrat na dan zvečer.
English: As for all medicines, data on the use of Rhokiinsa are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rhokiinsa stalno spremljajo.
English: Other information about Rhokiinsa
Slovenian: Druge informacije o zdravilu Rhokiinsa
English: Side effects reported with Rhokiinsa are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Rhokiinsa, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: In patients with moderately high eye pressure (up to 25 mmHg), Rhokiinsa was as effective as timolol (another medicine), lowering the pressure by around 3.9 mmHg to 4.7 mmHg, compared with reductions of 3.8 mmHg to 5.2 mmHg for patients using timolol.
Slovenian: Pri bolnikih z zmerno povišanim očesnim tlakom (do 25 mmHg) je bilo zdravilo Rhokiinsa enako učinkovito kot timolol (drugo zdravilo), saj je znižalo tlak med 3,9 mmHg in 4,7 mmHg v primerjavi z znižanjem od 3,8 mmHg do 5,2 mmHg pri bolnikih, ki so uporabljali timolol.
English: For more information about using Rhokiinsa, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Rhokiinsa glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Why is Rhokiinsa authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Rhokiinsa odobreno v EU?
English: This means that it blocks the activity of an enzyme called Rho kinase, which has a role in controlling drainage of fluid from the eye.
Slovenian: To pomeni, da zavira dejavnost encima, imenovanega Rho-kinaza, ki sodeluje pri nadzorovanju odtoka tekočine iz očesa.
English: An overview of Rhokiinsa and why it is authorised in the EU
Slovenian: Pregled zdravila Rhokiinsa in zakaj je odobreno v EU
English: However, when these results were combined with results from other studies, decreases in eye pressure with Rhokiinsa were larger than those seen in the main study only.
Slovenian: Ko pa so te rezultate združili z rezultati iz drugih študij, je bilo znižanje očesnega tlaka ob jemanju zdravila Rhokiinsa večje od vrednosti, opaženih v glavni študiji.
English: In terms of safety, the side effects of Rhokiinsa are considered manageable and were more likely to be confined to the eye.
Slovenian: Z vidika varnosti se neželeni učinki zdravila Rhokiinsa štejejo za obvladljive in so bolj verjetno omejeni na oko.
English: What benefits of Rhokiinsa have been shown in studies?
Slovenian: Kakšne koristi zdravila Rhokiinsa so se pokazale v študijah?
English: Rhokiinsa, which has a different mode of action from previously authorised treatments, provides another treatment option for patients with open-angle glaucoma and ocular hypertension.
Slovenian: Zdravilo Rhokiinsa, ki ima drugačen način delovanja od predhodno odobrenih zdravil, zagotavlja drugo možnost zdravljenja bolnikom z glavkomom odprtega zakotja in očesno hipertenzijo.
English: The effect of Rhokiinsa was less pronounced in patients whose eye pressure was more than 30 mmHg, but these results were considered less important because Rhokiinsa is not expected to be used on its own in this group.
Slovenian: Učinek zdravila Rhokiinsa je bil manj izrazit pri bolnikih, pri katerih je bil tlak v očesu višji od 30 mmHg, vendar so bili ti rezultati manj pomembni, ker se ne pričakuje, da se bo to zdravilo v tej skupini uporabljalo samostojno.
English: A main study of 708 patients with open-angle glaucoma or ocular hypertension showed that Rhokiinsa is effective at lowering eye pressure.
Slovenian: Glavna študija pri skupaj 708 bolnikih z glavkomom odprtega zakotja ali očesno hipertenzijo je pokazala, da je zdravilo Rhokiinsa učinkovito pri znižanju očesnega tlaka.
English: Other common side effects (which may affect up to 2 in 10 people) are: cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), eye pain, conjunctival haemorrhage (bleeding in the surface layer of the eye), erythema (reddening) at the site where the medicine was applied and the eyelid, corneal staining, blurred vision and increased lacrimation (watery eyes).
Slovenian: Drugi pogosti neželeni učinki (ki se pojavijo pri največ 2 bolnikih od 10) so: cornea verticillata (depoziti na roženici, tj. prozorni plasti na prednji strani očesa, ki pokriva zenico in šarenico), bolečina v očesu, krvavitev v veznico (krvavitev na površinski plasti očesa), eritem (pordelost) na mestu vkapanja zdravila in eritem veke, obarvanje roženice, zamegljen vid in povečano solzenje (solzne oči).
English: What is Rhokiinsa and what is it used for?
Slovenian: Kaj je zdravilo Rhokiinsa in za kaj se uporablja?
English: Rhokiinsa is an eye-drop solution that is used to reduce pressure inside the eye in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal).
Slovenian: Zdravilo Rhokiinsa je raztopina za kapljice za oko, ki se uporablja za zniževanje tlaka v očesu pri odraslih z glavkomom odprtega zakotja (boleznijo, pri kateri se očesni tlak zviša, ker tekočina ne more iztekati iz očesa) ali očesno hipertenzijo (kadar je očesni tlak višji od običajnega).
English: The most common side effect with Rhokiinsa (which may affect around 5 in 10 people) is conjunctival hyperaemia (increased blood supply to the eye, leading to redness).
Slovenian: Najpogostejši neželeni učinek zdravila Rhokiinsa (ki se lahko pojavi pri približno 5 bolnikih od 10) je hiperemija veznice (povečan dotok krvi v oko, kar povzroča pordečitev očesa).
English: When pressure in the eye is raised, it can cause damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Slovenian: Kadar je tlak v očesu povišan, lahko poškoduje mrežnico (membrano na zadnji strani zrkla, ki je občutljiva za svetlobo) in vidni živec, ki pošilja signale iz očesa v možgane.
English: What are the risks associated with Rhokiinsa?
Slovenian: Kakšna tveganja so povezana z zdravilom Rhokiinsa?
English: The active substance in Rhokiinsa, netarsudil, is a Rho kinase inhibitor.
Slovenian: Učinkovina v zdravilu Rhokiinsa, netarsudil, je zaviralec Rho-kinaze.
English: Rhokiinsa contains the active substance netarsudil.
Slovenian: Zdravilo Rhokiinsa vsebuje učinkovino netarsudil.
English: For the full list of side effects and restrictions with Rhokiinsa, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Rhokiinsa glejte navodilo za uporabo.
English: How is Rhokiinsa used?
Slovenian: Kako se zdravilo Rhokiinsa uporablja?
English: In patients whose eye pressure was higher than 25 mmHg, Rhokiinsa was less effective than timolol.
Slovenian: Zdravilo Rhokiinsa je bilo pri bolnikih z očesnim tlakom, višjim od 25 mmHg, manj učinkovito kot timolol.
English: Rhokiinsa showed good effects across a range of eye pressures.
Slovenian: Zdravilo je namreč pokazalo dobre učinke pri različnih vrednostnih očesnega tlaka.
English: How does Rhokiinsa work?
Slovenian: Kako zdravilo Rhokiinsa deluje?
English: When it blocks this enzyme, Rhokiinsa increases the flow of fluid out of the eyeball, thereby lowering pressure inside the eye. Rhokiinsa is also thought to lower eye pressure by reducing pressure in the veins around the eyes.
Slovenian: Zdravilo Rhokiinsa z zaviranjem tega encima poveča izcedek tekočine iz zrkla in s tem zniža tlak v očesu.
English: Rhokiinsa is only available on prescription and should be started by an eye specialist.
Slovenian: Predpisovanje in izdaja zdravila Rhokiinsa je le na recept, zdravljenje z njim pa sme uvesti samo oftalmolog.
English: Packaging Content Package size
Slovenian: Pot uporabe Pakiranje Vsebina Velikost pakiranja
English: Invented name
Slovenian: Številka EMA Izmišljen o ime
English: 1 bottle; 2 sachets
Slovenian: 2 vrečki
English: 1 bottle; 1 sachet
Slovenian: 1 vrečka
English: ATCvet code: QI06AJ03.
Slovenian: Oznaka ATCvet: QI06AJ03.
English: Date of first authorisation: 23/02/2005 Date of last renewal: 14/01/2010
Slovenian: Datum pridobitve dovoljenja za promet: 23/02/2005 Datum podaljšanja dovoljenja za promet: 14/01/2010
English: Shelf life after reconstitution according to directions: use immediately.
Slovenian: Rok uporabnosti po rekonstituciji v skladu z navodili : uporabite takoj.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
Slovenian: Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (pojavijo se pri več kot 1 živali od 10 živali med enim zdravljenjem) - pogosti (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 100 živali) - občasni (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 1.000 živali) - redki (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 10.000 živali) - zelo redki (pojavijo se pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
English: No effect other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
Slovenian: Drugi učinki, razen tistih, ki so navedeni v poglavju 4.6 »Neželeni učinki«, niso znani, razen povišane temperature , ki izjemoma lahko traja pet dni.
English: 1 cell culture infective dose 50%
Slovenian: 1 50% infektivni odmerek za celično kulturo
English: * less than 1 animal in 10,000 animals displaying adverse reaction(s) during the course of one treatment, including isolated reports.
Slovenian: * manj kot 1 živali od 10.000 živali kaže neželene učinke med trajanjem enega zdravljenja, vključujoč posamezne primere
English: EU/2/04/050/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/050/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
Slovenian: EU/2/04/050/001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/2/04/050/002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
English: Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis component and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Slovenian: Ponovno cepljenje: - prvo ponovno cepljenje je potrebno opraviti za vse komponente eno leto po osnovnem cepljenju, - nadaljnja ponovna cepljenja je potrebno opraviti: vsako leto za komponento klamidioze in v obdobjih do 3 leta za komponente rinotraheitisa, kaliciviroze in panleukopenije.
English: 2 egg infective dose 50%
Slovenian: 2 50% infektivni odmerek za embrionirana kokošja jajca
English: Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml solvent, both closed with a butyl elastomer closure and sealed with an aluminium or plastic cap.
Slovenian: Prebodna steklenička iz stekla tipa 1, ki vsebuje 1 odmerek liofilizata, in prebodna steklenička iz stekla tipa I, ki vsebuje vehikel; obe zaprti z gumijastim zamaškom in zaščiteni z aluminijasto ali plastično zaporko.
English: The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination.
Slovenian: Cepivo dokazano zmanjša izločanje kalici virusa mačk ob nastopu imunosti in do 1 leto po cepljenju.
English: Lyophilisate (10xdose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml)
Slovenian: Liofilizat (10 x 1 odmerek) in vehikel (10 x 1 ml) Liofilizat (50 x 1 odmerek) in vehikel (50 x 1 ml)
English: Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against Chlamydophila felis infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs.
Slovenian: Aktivna imunizacija 8 tednov starih mačk in starejših: - proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj, - proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj,
English: The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis component.
Slovenian: Trajanje imunosti je 3 leta po zadnjem ponovnem cepljenju za komponente kužnega rinotraheitisa, kaliciviroze in panleukopenije, ter 1 leto za komponento Chlamydophila felis.